Madden Securities’s Aquestive Therapeutics AQST Stock Holding History

Madden Securities’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5	Buy	+1	New	+$4	﹤0.01%	343

Other funds holding AQST

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

Trust Point Inc La Crosse, Wisconsin $1.33B AUM 20.56% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.68B AUM 22.33% 1-Year Est. Return

Madden Securities's AQST Position: Q3 2026 in Review

Madden Securities opened a new position in Aquestive Therapeutics (AQST) in Q3 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #343 among its holdings.

35 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Madden Securities held 1 share of Aquestive Therapeutics worth $5 as of Q3 2026.
Aquestive Therapeutics was a new Madden Securities position in Q3 2026.
Aquestive Therapeutics made up ﹤0.01% of Madden Securities's portfolio in Q3 2026, its #343 holding.
35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Madden Securities's 13F filing for Q3 2026, filed 27 Oct 2026.